These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 12682161)

  • 81. Modulation of fibronectin adhesins and other virulence factors in a teicoplanin-resistant derivative of methicillin-resistant Staphylococcus aureus.
    Renzoni A; Francois P; Li D; Kelley WL; Lew DP; Vaudaux P; Schrenzel J
    Antimicrob Agents Chemother; 2004 Aug; 48(8):2958-65. PubMed ID: 15273106
    [TBL] [Abstract][Full Text] [Related]  

  • 82. In vivo efficacy and pharmacokinetics of AC98-6446, a novel cyclic glycopeptide, in experimental infection models.
    Weiss WJ; Murphy T; Lenoy E; Young M
    Antimicrob Agents Chemother; 2004 May; 48(5):1708-12. PubMed ID: 15105124
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Alterations of cell wall structure and metabolism accompany reduced susceptibility to vancomycin in an isogenic series of clinical isolates of Staphylococcus aureus.
    Sieradzki K; Tomasz A
    J Bacteriol; 2003 Dec; 185(24):7103-10. PubMed ID: 14645269
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains.
    Sakoulas G; Moellering RC
    Clin Infect Dis; 2008 Jun; 46 Suppl 5():S360-7. PubMed ID: 18462091
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Treatment of bacteraemia: meticillin-resistant Staphylococcus aureus (MRSA) to vancomycin-resistant S. aureus (VRSA).
    Gould IM
    Int J Antimicrob Agents; 2013 Jun; 42 Suppl():S17-21. PubMed ID: 23664580
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Evolution of a vancomycin-intermediate Staphylococcus aureus strain in vivo: multiple changes in the antibiotic resistance phenotypes of a single lineage of methicillin-resistant S. aureus under the impact of antibiotics administered for chemotherapy.
    Sieradzki K; Leski T; Dick J; Borio L; Tomasz A
    J Clin Microbiol; 2003 Apr; 41(4):1687-93. PubMed ID: 12682161
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05.
    Steinkraus G; White R; Friedrich L
    J Antimicrob Chemother; 2007 Oct; 60(4):788-94. PubMed ID: 17623693
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group.
    Smith TL; Pearson ML; Wilcox KR; Cruz C; Lancaster MV; Robinson-Dunn B; Tenover FC; Zervos MJ; Band JD; White E; Jarvis WR
    N Engl J Med; 1999 Feb; 340(7):493-501. PubMed ID: 10021469
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Impact of vancomycin MIC creep on patients with methicillin-resistant Staphylococcus aureus bacteremia.
    Yeh YC; Yeh KM; Lin TY; Chiu SK; Yang YS; Wang YC; Lin JC
    J Microbiol Immunol Infect; 2012 Jun; 45(3):214-20. PubMed ID: 22571999
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Vancomycin MICs and risk of complicated bacteremia by glycopeptide-susceptible Staphylococcus aureus.
    Falcón R; Mateo E; Oltra R; Giménez E; Albert E; Torres I; Navarro D
    Eur J Clin Microbiol Infect Dis; 2019 May; 38(5):903-912. PubMed ID: 30729396
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Microbiological and genotypic analysis of methicillin-resistant Staphylococcus aureus bacteremia.
    McCalla C; Smyth DS; Robinson DA; Steenbergen J; Luperchio SA; Moise PA; Fowler VG; Sakoulas G
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3441-3. PubMed ID: 18606839
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Multiplex PCR strategy for rapid identification of structural types and variants of the mec element in methicillin-resistant Staphylococcus aureus.
    Oliveira DC; de Lencastre H
    Antimicrob Agents Chemother; 2002 Jul; 46(7):2155-61. PubMed ID: 12069968
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Secrets of success of a human pathogen: molecular evolution of pandemic clones of meticillin-resistant Staphylococcus aureus.
    Oliveira DC; Tomasz A; de Lencastre H
    Lancet Infect Dis; 2002 Mar; 2(3):180-9. PubMed ID: 11944188
    [TBL] [Abstract][Full Text] [Related]  

  • 94. The evolution of methicillin resistance in Staphylococcus aureus: similarity of genetic backgrounds in historically early methicillin-susceptible and -resistant isolates and contemporary epidemic clones.
    Crisóstomo MI; Westh H; Tomasz A; Chung M; Oliveira DC; de Lencastre H
    Proc Natl Acad Sci U S A; 2001 Aug; 98(17):9865-70. PubMed ID: 11481426
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Similarity of antibiotic resistance patterns and molecular typing properties of methicillin-resistant Staphylococcus aureus isolates widely spread in hospitals in New York City and in a hospital in Tokyo, Japan.
    Aires de Sousa M; de Lencastre H; Santos Sanches I; Kikuchi K; Totsuka K; Tomasz A
    Microb Drug Resist; 2000; 6(3):253-8. PubMed ID: 11144426
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Distribution of methicillin-resistant Staphylococcus aureus clones among health care facilities in Connecticut, New Jersey, and Pennsylvania.
    Roberts RB; Chung M; de Lencastre H; Hargrave J; Tomasz A; Nicolau DP; John JF; Korzeniowski O;
    Microb Drug Resist; 2000; 6(3):245-51. PubMed ID: 11144425
    [TBL] [Abstract][Full Text] [Related]  

  • 97.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 98.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 99.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 100.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.